Neurology & Psychiatry · LP-153
Carbamazepine Tablets
Generic medicine development record. Review the proposed presentation and the professional reference information below.
Development record
- Portfolio reference
- LP-153Neurology & Psychiatry
- Generic identity
- CarbamazepineTablet
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Ingredient reference
Record identity and reference background.
- Portfolio reference
- LP-153
- Generic ingredient
- Carbamazepine
- Dosage form
- Tablet
- Proposed strength
- 100 mg; 200 mg; 400 mg controlled-release
- Proposed pack
- Blister 10 x 10 tablets
- Portfolio category
- Neurology & Psychiatry
About Carbamazepine
Carbamazepine is an antiseizure medicine that also has selected uses in neuralgia and mood disorders. Its effects on nerve signalling differ from those of many other neurological medicines, so choice depends on the diagnosis and seizure type. This record includes conventional strengths and a controlled-release presentation. Release characteristics are clinically meaningful and cannot be inferred from the ingredient name or tablet appearance.
How to read this profile
Scientific information relates to the ingredient and dosage-form context. It is not approved Luang Pharma labelling, a clinical recommendation, or evidence of equivalence to a referenced product. Multiple strengths or presentations represent separate proposed variants and must not be treated as interchangeable.
02 · Professional background
Scientific & clinical reference
Read the clinical context, selected safety considerations and presentation-specific information below.
Clinical context and therapeutic role
Epilepsy management requires accurate classification of seizures, review of control and tolerability, and continuity of the prescribed formulation. Neuralgia or mood-disorder use involves different treatment goals. Carbamazepine has substantial interaction potential because it affects drug-metabolizing enzymes. A catalogue containing several presentations is not a substitution guide. Any change between release types or products should be assessed by the responsible prescriber and pharmacist.
Important safety considerations
Severe skin reactions, blood-cell disorders, liver injury and low sodium are important risks, alongside dizziness, drowsiness and impaired coordination. Relevant ancestry may inform genetic testing for serious skin-reaction risk under applicable guidance. Pregnancy and contraception need specialist review because of fetal risk and interactions with hormonal contraceptives. A new rash with systemic symptoms needs urgent assessment. Abrupt withdrawal can provoke seizures, and therapy changes should be supervised.
These are selected considerations, not a complete list. Use the current instructions or approved label for the exact authorised product and seek appropriate professional advice.
Presentation, handling and storage
The 400 mg controlled-release entry must be distinguished from conventional tablets. Do not assume all strengths share a release system or that any can be crushed. Exact salt identity, release designation and presentation-level authorization require confirmation.
Keep the medicine in the labelled original pack with its leaflet. Check the expiry date and pack integrity before dispensing. The authorized label must determine storage temperature, protection from moisture or light, and disposal; no shelf life or in-use period can be established from a catalogue entry.
Final composition, instructions, shelf life and storage conditions are not established by this portfolio entry. They must come from the controlled documentation for the specific product.
Points for professional review
Review seizure or other diagnosis, prior reactions, blood count, sodium, liver function, interaction burden and reproductive considerations. Confirm the prescribed release type and continuity requirements.
03 · Product enquiry
Documentation & regulatory status
Evidence status
What is established — and what remains open
This record has received an editorial evidence-layer review. The review separates catalogue facts from unresolved product-specific fields and external context; it is not medical, regulatory or market-authorisation approval.
Layer 01
Controlled catalogue facts
- Generic ingredient
- Carbamazepine
- Dosage form / presentation
- Tablet
- Catalogue strength
- 100 mg; 200 mg; 400 mg controlled-release
- Catalogue pack
- Blister 10 x 10 tablets
- Portfolio category
- Neurology & Psychiatry
Layer 02
Unresolved product-specific fields
- P008 — Release characteristics are embedded in the strength text: 100 mg; 200 mg; 400 mg controlled-release. Controlled-release status must not be propagated to unspecified strengths.
- Exact release designation, release technology, scoring/crushing restrictions and strength-to-pack mapping require variant-level evidence.
- Approved indication, patient eligibility and dosing are not established by this portfolio record.
- Registration, manufacturing/site status, supply availability, storage conditions and shelf life remain product- and market-specific evidence items.
Layer 03
Attributed external context
- MedlinePlus: Carbamazepinegovernment-hosted medicine monograph
- DailyMed: carbamazepine extended-release tablets — external reference labelgovernment-hosted external product label
These references provide scientific or regulatory context only. They are not Luang Pharma product labelling, registration, manufacturing evidence, equivalence evidence or confirmation of supply.
Layer 04
Documents required to close the record
- Variant matrix confirming which strengths are conventional versus controlled-release, including release technology and administration restrictions.
- Destination-market authorisation or other lawful supply-route evidence plus the approved label/leaflet/IFU, where applicable.
- Product-specific composition/excipient, storage, shelf-life and pack-control documentation.
- Manufacturing-site and supply-status evidence before any public claim of installed capability, registration, availability or equivalence.
For LP-153, identify the destination country, intended professional use, proposed presentation and the role of your organisation. The appropriate supply route and available documentation must be confirmed for that case.
- Confirm the legal entity, manufacturing site and authorised scope for the proposed supply chain.
- Confirm product registration or another lawful route, approved labelling and the applicable destination requirements.
- Request relevant product information, specifications and supporting evidence through the company contact.
- Confirm storage, transport, traceability, complaints and safety-reporting responsibilities before any agreement.
The public catalogue extends beyond the initial planned facility modules. A listing does not mean that the dosage form is installed, qualified or licensed at Boten.
04 · External sources
Sources and further reading
- MedlinePlus: Carbamazepine — ingredient/formulation reference
- DailyMed: carbamazepine extended-release tablets — external reference label
External sources are provided for reference. Their authors do not endorse Luang Pharma, and another product’s authorisation does not transfer to this portfolio record. Source availability and wording can change.
Professional enquiries
Request product-specific evidence for LP-153.
State the exact presentation, organisation, destination and evidence needed. This public record is not an offer of supply.